Chemotherapy can cause blood in the stool, and it does so more often than many patients expect. The bleeding can arise through several distinct pathways: direct damage to the gut lining, a drop in the blood cells responsible for clotting, severe intestinal inflammation triggered by immune suppression, or infections that take hold while the body’s defenses are down. Because the causes differ, so do the urgency and the treatment, which makes understanding what is happening in your gut during chemotherapy genuinely useful rather than merely academic.
Direct Damage to the Intestinal Lining
The cells lining your intestines are among the fastest-dividing cells in the body, which is exactly why chemotherapy hits them hard. Most chemotherapy drugs work by targeting rapidly dividing cells, and they cannot distinguish a cancer cell from a healthy gut cell that happens to be dividing at a similar pace. The result is a condition called mucositis, where the protective inner surface of the intestine breaks down. Chemotherapy triggers cell death in the intestinal lining and halts normal cell turnover, leading to structural damage including loss of the tiny finger-like projections that absorb nutrients and maintain a barrier between the gut contents and the bloodstream.1PubMed. Roles of growth factors in chemotherapy-induced intestinal mucosal damage repair When that barrier breaks down, the raw, damaged tissue can bleed. Sometimes the bleeding is microscopic and only shows up on a lab test; other times it is visible as red or dark streaks in the stool.
Mucositis can affect any part of the gastrointestinal tract, from the mouth all the way to the rectum. You may have heard of mouth sores during chemotherapy, and intestinal mucositis is essentially the same process happening further down the digestive system. The severity depends partly on which drugs are used, how high the doses are, and how many cycles you have received. Platinum-based drugs like cisplatin are well-known triggers of intestinal mucositis, and researchers continue to study anti-inflammatory agents that might protect the gut during treatment.2The Journal of Immunology. Protective effect of recombinant thrombomodulin on chemotherapy-induced intestinal mucosal injury in mice For now, though, mucositis remains one of the most common dose-limiting side effects of chemotherapy.
When Platelet Counts Drop
A second pathway to blood in the stool has nothing to do with the gut lining being damaged directly. Chemotherapy frequently suppresses the bone marrow, which is where new blood cells are made. One consequence is a drop in platelets, the small cell fragments that help blood clot. This condition, called chemotherapy-induced thrombocytopenia, is a common complication of treatment, particularly in gastrointestinal cancers, and it raises the risk of bleeding throughout the body, including from the digestive tract.3PubMed Central. Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment
What determines how likely you are to bleed depends largely on how far platelets fall. Research on bleeding risk in patients with low platelets has shown that the platelet count itself is the strongest predictor, along with factors like active inflammation and kidney problems.4PubMed. Effect of beta-blockers, Ca2+ antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia In practice, this means that a patient whose platelets have dropped to very low levels can develop bleeding from sites that would normally seal themselves without trouble, such as small irritations or minor ulcers in the stomach or colon that would barely ooze in a person with normal clotting ability. The blood may appear as bright red if the source is in the lower intestine, or dark and tarry if it originates higher up in the digestive tract.
Thrombocytopenia often leads oncologists to delay treatment cycles or reduce doses, because continuing chemotherapy while platelets are critically low creates a real risk of serious hemorrhage. If you notice blood in your stool during a treatment cycle, your medical team will almost certainly check your platelet count early in the evaluation.
Neutropenic Enterocolitis
One of the more dangerous causes of bloody stool during chemotherapy is a condition called neutropenic enterocolitis, sometimes referred to as typhlitis. This happens when chemotherapy drives the white blood cell count so low that the gut wall itself becomes inflamed and vulnerable to bacterial invasion. The hallmark symptoms are fever, abdominal pain, cramping, diarrhea, and gastrointestinal bleeding in a patient whose immune cell counts have bottomed out.5Clinical Infectious Diseases. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy
Neutropenic enterocolitis has become a growing concern as more aggressive chemotherapy regimens have entered common use. It most often develops in patients being treated for blood cancers like leukemia, where the chemotherapy is particularly intensive, but it can occur with solid tumor regimens too.6PubMed. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography The cecum, the pouch-like beginning of the large intestine, is the most commonly affected area, which is why older literature often called this condition “typhlitis” from the Greek word for cecum. Doctors typically look for thickening of the bowel wall on imaging, and a wall thicker than about four millimeters in a neutropenic patient with the right symptoms raises the alarm.5Clinical Infectious Diseases. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy
This is a medical emergency. The inflamed, thinned-out bowel wall can perforate, leading to life-threatening infection in the abdominal cavity. If you develop fever, worsening belly pain, and bloody diarrhea during a period of known low white blood cell counts, that combination warrants an immediate call to your oncology team or a trip to the emergency room.
Infections That Cause Bloody Diarrhea
Chemotherapy weakens the immune system, and a suppressed immune system is an open invitation for opportunistic infections in the gut. One of the best-known culprits is Clostridioides difficile (commonly called C. diff), a bacterium that can cause severe diarrhea, inflammation of the colon, and visible blood in the stool. Studies have documented C. diff diarrhea triggered specifically by cancer chemotherapy, with patients developing dehydration, toxemia, and bloody stools that were confirmed by endoscopy and toxin testing.7PubMed. Clostridium difficile diarrhea induced by cancer chemotherapy
C. diff is usually associated with antibiotic use, but chemotherapy drugs themselves can disrupt the normal bacterial balance of the gut enough to let C. diff flourish. Cancer patients also tend to receive antibiotics for various reasons during treatment, compounding the risk. In some cases, C. diff is not acting alone. One case report described a patient who developed intractable diarrhea from a co-infection of C. diff and cytomegalovirus, with stool tests showing both white blood cells and occult blood.8PubMed Central. A rare case intractable diarrhea secondary to Clostridium difficile and cytomegalovirus coinfection Viral reactivation of cytomegalovirus is another concern during chemotherapy-induced immune suppression, and when it hits the colon, it can cause ulceration and bleeding of its own.
The practical takeaway is that not all bloody diarrhea during chemotherapy stems from the drugs themselves. Your doctor will often test for C. diff and other infections before assuming the bleeding is a direct drug effect, because the treatment for an infection is antibiotics or antivirals rather than adjusting your chemotherapy.
Targeted Therapies and Bleeding
Traditional cytotoxic chemotherapy is not the only cancer treatment linked to gastrointestinal bleeding. Newer targeted therapies, particularly drugs that block the growth of new blood vessels to starve tumors of their blood supply, carry their own bleeding risks. Bevacizumab, one of the most widely used of these anti-angiogenic agents, has been studied extensively for this side effect. A meta-analysis found that roughly a third of patients receiving bevacizumab experienced some grade of bleeding, with the risk about three times higher than in control groups receiving chemotherapy alone.9Journal of Clinical Oncology. Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: A meta-analysis
Most of that bleeding is low-grade, things like nosebleeds or minor gum bleeding, but about 3% of patients developed severe bleeding events. The risk was not uniform across cancer types. Patients with colorectal cancer had a particularly elevated risk, with bleeding rates over six times higher than controls, while patients with kidney cancer also saw substantially increased rates.9Journal of Clinical Oncology. Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: A meta-analysis Because bevacizumab works by interfering with blood vessel formation and maintenance, it can weaken the integrity of existing blood vessels in the gut wall, making them more prone to leaking or rupturing. If you are receiving a combination regimen that includes bevacizumab or a similar agent, your oncologist will be monitoring for bleeding signs closely.
When Chemotherapy Is Combined With Radiation
Patients with pelvic cancers, including rectal, cervical, and prostate cancers, often receive chemotherapy alongside radiation therapy. Radiation to the pelvis can damage the rectum and lower colon, causing a condition known as radiation proctitis, which involves inflammation, ulceration, and bleeding from the rectal lining. This is recognized as a significant complication of combined treatment for pelvic cancers.10Grekov’s Bulletin of Surgery. Surgical treatment of rectal bleeding in comorbid patients with chronic radiation proctitis
Radiation proctitis can be acute, appearing during or shortly after treatment, or chronic, surfacing months or even years later. The chronic form is the one that tends to cause persistent or recurrent rectal bleeding that patients find alarming. Chemotherapy given alongside radiation can make the gut more sensitive to radiation damage, so the combination often produces more severe mucosal injury than either treatment alone. For patients who develop chronic radiation proctitis with ongoing bleeding, treatment options range from topical therapies applied during endoscopy to, in severe cases, surgical intervention.
Distinguishing Causes and Getting the Right Workup
When blood appears in the stool during chemotherapy, the cause is not always obvious, and oncology teams typically work through a process of elimination. Blood counts will reveal whether thrombocytopenia is a factor. Stool tests can check for C. diff and other infections. Imaging can look for signs of neutropenic enterocolitis or other structural problems. And in some cases, endoscopy may be needed to directly visualize the source of bleeding.
Endoscopy in chemotherapy patients carries its own considerations, because many of these patients have low platelet counts or low white blood cell counts at the time they develop bleeding. A study looking at the safety of endoscopy in cancer patients with these abnormalities found that about 5% experienced a bleeding complication and about 4% had an infectious complication within a week of the procedure. Very low platelet counts, roughly below 50,000 per microliter, were the strongest predictor of bleeding after the procedure.11PubMed Central. Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia This means doctors have to weigh the diagnostic benefit of the procedure against the procedural risk, and sometimes platelet transfusions are given beforehand to reduce that risk.
It is worth noting that gastrointestinal bleeding in cancer patients, regardless of its specific cause, is a major contributor to illness and can be life-threatening.12PubMed Central. Gastrointestinal bleeding: imaging and interventions in cancer patients This is not a symptom to “wait and see” about. Even a small amount of visible blood in the stool warrants a call to your oncology team, because the underlying cause could range from something manageable to something that needs urgent treatment.
What You Can Do Before and During Treatment
There is no foolproof way to prevent gastrointestinal bleeding during chemotherapy, but a few practical steps can reduce the risk or help catch problems early. Staying well-hydrated supports gut function and helps your body recover from mucosal damage. Avoiding nonsteroidal anti-inflammatory drugs like ibuprofen during chemotherapy is important because they irritate the stomach lining and interfere with platelet function, compounding both of the major bleeding pathways discussed above. Your oncologist may recommend acetaminophen instead for pain or fever.
Pay attention to what your stool looks like. Bright red blood usually indicates a source in the lower intestine or rectum. Dark, tarry, or black stools suggest bleeding higher up in the digestive tract, such as in the stomach or small intestine. Either warrants a report to your care team, but the appearance gives useful information about where the problem might be. Occult bleeding, meaning blood that is present but not visible, can show up as unexplained anemia or fatigue. If your hemoglobin drops during treatment without an obvious explanation, hidden GI bleeding is one of the things your doctor will consider.
Some patients undergoing aggressive regimens receive prophylactic platelet transfusions when counts fall below a certain threshold, and growth factor injections to boost white blood cell production are routine in many protocols. These interventions do not directly prevent gut damage, but they address two of the conditions that turn minor mucosal irritation into significant bleeding. If your care team is monitoring your blood counts closely between cycles, which they almost certainly are, those numbers guide decisions about when to proceed with the next dose and when to hold.
Bloody Stool That Is Not From Treatment
One thing that trips up both patients and sometimes clinicians is assuming that every instance of blood in the stool during chemotherapy is caused by the treatment. Cancer patients are still susceptible to all the ordinary causes of gastrointestinal bleeding that affect the general population. Hemorrhoids, which are extremely common and can be aggravated by the constipation or diarrhea that chemotherapy causes, are a frequent source of bright red blood on the toilet paper or in the bowl. Peptic ulcers, diverticular disease, and inflammatory bowel conditions can all produce bleeding independently of chemotherapy.
There is also the possibility that the cancer itself is bleeding. Tumors in the colon, rectum, stomach, or small intestine can erode into blood vessels and cause intermittent or steady bleeding. In patients being treated for gastrointestinal cancers, new bleeding could represent disease progression rather than a treatment side effect. This is another reason why reporting the symptom rather than self-diagnosing is essential: the workup may reveal something that changes the treatment plan entirely.
Patients who were taking blood thinners before their cancer diagnosis, or who require anticoagulation for reasons like blood clots during treatment, face an additional layer of complexity. The interaction between anticoagulant therapy and chemotherapy-induced thrombocytopenia can amplify bleeding risk substantially, and managing those competing needs is one of the trickier balancing acts in oncology care. If you are on any form of blood thinner during chemotherapy, your team will be watching your clotting parameters especially carefully.